Biobanks could identify medically actionable findings relevant for COVID-19 clinical care
- 15 June 2020
- journal article
- letter
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 26 (7), 991
- https://doi.org/10.1038/s41591-020-0953-x
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Evidence‐based assessments of clinical actionability in the context of secondary findings: Updates from ClinGen's Actionability Working GroupHuman Mutation, 2018
- Exome Sequencing–Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank ParticipantsJAMA Network Open, 2018
- Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and GenomicsGenetics in Medicine, 2017
- Aggregate penetrance of genomic variants for actionable disorders in European and African AmericansScience Translational Medicine, 2016
- ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencingGenetics in Medicine, 2013